The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Biotinylated dextran amine

Biotinylated dextran amine

Biotinylated dextran amine is a versatile reagent used in various biomedical research applications.
It consists of a dextran backbone with biotin moieties attached, enabling the labeling and detection of target molecules.
This powerful tool allows researchers to track and visualize cellular processes, protein interactions, and more.
With its high specificity and sensitivity, biotinylated dextran amine is a valuable asset for advanced studies in cell biology, immunology, and molecular biology.
Leveraging PubCompare.ai's AI-driven platform, researchers can easily identify the optimal protocols and products to streamline their work and achieve better results.

Most cited protocols related to «Biotinylated dextran amine»

The experiments were carried out on thirteen (3.5–6.9 years old) rhesus (Macaca mulatta) or cynomolgus (Macaca fascicularis) monkeys (male or female, 3.0–5.0 kg; see Table 1), in accordance to the Guide for Care and Use of Laboratory Animals (ISBN 0-309-05377-3; 1996) and approved by local veterinary authorities, including the ethical assessment by the local (cantonal) Survey Committee on Animal Experimentation and a final acceptance delivered by the Federal Veterinary Office (BVET, Bern, Switzerland). The monkeys were obtained from our own colony in our animal facility (Macaca fascicularis) or were purchased (Macaca fascicularis and Macaca mulatta) from a certified supplier (BioPrim; 31450 Baziège; France), with the authorization to import the animals delivered by the Federal Veterinary Office (BVET, Bern, Switzerland). Three recent reports (Wannier et al., 2005 (link); Freund et al., 2006a (link), 2007 (link)) describe the behavioral task analyzed in the present report (‘modified Brinkman board’ task; see Fig. 1E and also http://www.unifr.ch/neuro/rouiller/motorcontcadre.htm), the surgical procedures (including transection of the CS tract in the cervical cord at C7/C8 level), the treatment with the anti-Nogo-A (n = 7) or control (n = 6) antibodies and the neuroanatomical investigations (including assessment of spinal lesion location and extent). The antibodies’ characteristics and penetration in the central nervous system have been reported elsewhere (Weinmann et al., 2006 (link); Freund et al., 2007 (link)). As previously reported in detail (Schmidlin et al., 2004 (link), 2005 (link); Wannier et al., 2005 (link); Freund et al., 2006a (link), 2007 (link)).
The present study includes the same twelve previously reported monkeys (Freund et al., 2006a (link), 2007 (link)) and a thirteenth monkey (Mk-AK), on which the experiment was completed later, and in which anti-Nogo-A antibody infusion was initiated 7 days post-lesion (Fig. 1A), in contrast to immediate infusion the day of the lesion in the other six anti-Nogo-A antibody-treated monkeys. However, in this thirteenth monkey (Mk-AK), although an osmotic pump was implanted immediately after the lesion (as was the case for all the other monkeys), only saline (NaCl 0.9%) was delivered during the first week, and delayed administration of the anti-Nogo-A antibody started 1 week post-lesion. In all cases, the antibody was delivered for a period of 4 weeks.
The monkeys’ identification codes refer to individual monkeys (Table 1 in Freund et al., 2006a (link)) and comprise, for the sake of clarity, a ‘C’ or an ‘A’ in the fourth character position, indicating whether the monkey was control antibody-treated or anti-Nogo-A antibody-treated, respectively. However, during the course of the experiments the animals had different names from which the experimenter could not deduce which antibody was infused, at least for the monkeys in which the experimenter-blind procedure was applied (Table 1).
Monkeys were housed in our animal facilities in rooms of 12 m3, each usually containing 2–4 monkeys free to move in the room and to interact with each other. In the morning, before behavioral testing, the animal keeper placed the monkeys in temporary cages for subsequent transfer to the primate chair. The monkeys had free access to water and were not food-deprived. The rewards obtained during the behavioral tests represented the first daily access to food. After the tests, the monkeys received additional food (fruits and cereals). The dexterity of each hand was assessed in all lesioned monkeys with a finger prehension task, specifically our modified Brinkman board quantitative test (Fig. 1E; see also Rouiller et al., 1998 (link); Liu & Rouiller, 1999 (link); Schmidlin et al., 2004 (link)). The tests were conducted using a Perspex board (10 cm × 20 cm) containing 50 randomly distributed slots, each filled with a food pellet at the beginning of the test (home-made behavioral apparatus). Twenty-five slots were oriented horizontally and twenty-five vertically. The dimensions of the slots were 15 mm long, 8 mm wide and 6 mm deep. Retrieval of the food pellets required fractionated finger movements, in order to produce an opposition of the index finger and the thumb, which corresponds to the precision grip. This manual prehension dexterity task was executed daily, alternatively with one and the other hand, four or five times per week for several months before and after the unilateral cervical cord lesion. A daily behavioral session typically lasted 60 min. The performance of each hand was videotaped. In the present study, two parameters were assessed: (i) the retrieval score, i.e. the number of wells from which the food pellets were successfully retrieved and brought to the mouth during 30 s, separately for the vertical and the horizontal slots; (ii) the contact time, defined as the time of contact (in s) between the fingers and the pellet, calculated for the first vertical slot and the first horizontal slot targeted by the monkey in a given daily session (see also paragraph 2 in the Results section). The contact time is comparable to the prehension time as introduced by Nishimura et al. (2007) (link) in parallel to the present study, but for a different grasping task. In our previous study, the retrieval score represented the primary outcome measure from the modified Brinkman board task (Freund et al., 2006a (link)) and was determined by the total number of pellets retrieved in 30 s. In the present study separate scores are provided for vertical and horizontal slots. The contact time data and the bivariate and trivariate statistical analyses (see below) represent secondary outcome measures from the modified Brinkman board task, newly introduced in the present report.
After the monkeys reached a level of performance corresponding to a plateau (usually after 30–60 days of initial training), we used the score from 30–50 daily sessions to establish a pre-lesion behavioral score for each monkey. A unilateral cervical cord lesion was performed in thirteen monkeys as follows. Intramuscular injection of ketamine (Ketalar® Parke-Davis, 5 mg/kg, i.m.) was delivered to induce anesthesia followed by an injection of atropine (i.m.; 0.05 mg/kg) to reduce bronchial secretions. In addition, before surgery, the animal was treated with the analgesic Carprofen (Rymadil®, 4 mg/kg, s.c.). A continuous perfusion (0.1 ml/min/kg) through an intravenous catheter placed in the femoral vein delivered a mixture of 1% propofol (Fresenius®) and a 4% glucose solution (1 volume of propofol and 2 volumes of glucose solution) to induce a deep and stable anesthesia. The animal's head was placed in a stereotaxic headholder, using ear bars covered at their tip with local anesthetic. The surgery was carried out under aseptic conditions, with continuous monitoring of the following parameters: heart rate, respiration rate, expired CO2, arterial O2 saturation and body temperature. In early experiments, an extra intravenous bolus of 0.5 mg of ketamine diluted in saline (0.9%) was added at potentially more painful steps of the surgical procedure (e.g. laminectomy) whereas, in later experiments, ketamine was added to the perfusion solution and delivered throughout surgery (0.0625 mg/min/kg). The animal recovered from anesthesia 15–30 min after the propofol perfusion was stopped, and was treated post-operatively with an antibiotic (Ampiciline 10%, 30 mg/kg, s.c.). Additional doses of Carprofen were given daily (pills of Rymadil mixed with food) for about 2 weeks after the surgery. Following the cervical cord lesion, the animal was kept alone in a separate cage for a couple of days in order to perform a careful survey of its condition. The details of surgical procedures and lesioning are available in previous reports (Schmidlin et al., 2004 (link), 2005 (link); Wannier et al., 2005 (link); Freund et al., 2006a (link), 2007 (link)).
After lesion, and following the period of recovery lasting generally 30–40 days, a post-lesion level of performance corresponding to a plateau was established, based on a block of ten behavioral sessions (usually the last ten sessions conducted). For the retrieval score, functional recovery was expressed quantitatively as the ratio (expressed as a percentage) of the post-lesion average retrieval score value to the pre-lesion average score value. Because contact time was measured only for the first vertical and first horizontal slots targeted by the monkey, in order to minimize the impact of outliers the pre-lesion and post-lesion contact time was assessed as the median value (Fig. 3C and D). Considering that good performance is reflected by a short contact time (in the pre-lesion condition), post-lesion performance (recovery) was expressed quantitatively as the ratio (expressed as a percentage) of the pre-lesion median contact time to the post-lesion median contact time. For measures of both recovery of score and contact time, if the calculated values exceeded 100% (i.e. post-lesion performance was better than pre-lesion performance), the recovery was considered to be complete and therefore expressed quantitatively as 100%.
Besides the new behavioral parameter of contact time introduced here, the present study also comprises a new analysis regarding the lesion size. In our previous reports (Freund et al., 2006a (link), 2007 (link)), the extent of the lesion was expressed as a percentage of the corresponding hemi-cord surface, as assessed from a 2-D reconstruction of the lesion in the transverse plane (see Fig. 1B and C). These standard values of lesion extent have been considered here again in Figs 2 and 4 (see also Table 1). The present study expands upon these data by further calculating the estimated volume of the cervical lesion in order to consider the extent of the lesion in 3-D. After completion of the post-lesion behavioral analysis (see below), the monkeys were killed and prepared for histology as follows. Each monkey was pre-anaesthetized with ketamine (5 mg/kg, i.m.) and given an overdose of sodium pentobarbital (Vetanarcol; 90 mg/kg, i.p.). Transcardiac perfusion of saline (0.9%) was followed by paraformaldehyde (4% in phosphate buffer 0.1 m, pH 7.4), and 10, 20 and 30% solutions of sucrose in phosphate buffer. The brain and the spinal cord were dissected and stored overnight in a solution of 30% sucrose in phosphate buffer. Frozen sections (50 μm thick) of the cervical cord (approximately segments C6-T3) were cut in the parasagittal longitudinal plane and collected in three series for later histological processing (see below).
Using an ad hoc function of the Neurolucida software (based on the Cavalieri method; MicroBrightField, Inc., Colchester, VT, USA), the volume of the cervical lesion (in mm3) was extrapolated from the reconstructions of the lesion on consecutive histological longitudinal sections of the cervical cord (see Table 1). The volume measurement of the cervical lesion was conducted on one out of three series of sagittal sections (50 μm thick), treated immunocytochemically with the SMI-32 antibody (Covance, Berkeley, CA, USA), as previously reported (Liu et al., 2002 (link); Beaud et al., 2008 (link); Wannier-Morino et al., 2008 (link)). The epitope recognized by the SMI-32 antibody lies on nonphosphorylated regions of neurofilament protein and is only expressed by specific categories of neurons (Campbell & Morrison, 1989 (link); Tsang et al., 2006 (link)). The other two series of sections were processed to visualize biotinylated dextran amine (BDA; Invitrogen, Molecular Probe, Eugene, OR, USA) and fluorescein dextran amine (Invitrogen, Molecular Probe, Eugene, OR, USA) staining, resulting from injections of BDA in the contralesional motor cortex and fluorescein dextran amine in the ipsilesional motor cortex (see Freund et al., 2006a (link), 2007 (link)). Measurements of volume of the cervical lesion were also conducted on sections processed for BDA but the lesion contour was not as well defined as on the SMI-32-stained sections, where a clear scar region could be distinguished from a penumbra lesion at the periphery of the lesion (yellow and red outlines in Fig. 1D). The scar region was characterized by a dense fibrous tissue or granulous tissue forming a central zone of the lesion where the SMI-32 staining was absent. The lesion volume data presented (Table 1, Fig. 5) and considered for statistical analysis (Table 2) are the measurements corresponding to the scar as seen on the SMI-32-stained sections.
Because of the limited number of animals, two independent statistical tests were used to compare the group of control antibody-treated monkeys (n = 6) with the group of anti-Nogo-A antibody-treated monkeys (n = 7). The first test (based on a linear Fisher discriminant analysis) takes into account one of the two parameters reflecting the size of the lesion (i.e. the extent of hemi-cord lesion or the volume of the lesion) and one of the four parameters reflecting the percentage of functional recovery (score for vertical slots, score for horizontal slots; contact time for vertical slots or contact time for horizontal slots), and thus is aimed at assessing the overlap or segregation between the two groups of data (Figs 2E and F, and 4C and D). The test provides maximal separation between the groups (see Everitt, 2005 ) in the form of a linear function of the observed variables such that the ratio of the between-groups variance to its within-group variance is maximized. We used the R package to get the two lines plotted in each of Figs 2E and F, and 4C and D. Line 1 (dashed line) yields maximal separation and the projected samples are provided on the orthogonal line 2 (solid line). For better visualization, line 2 was proportionally enlarged and positioned vertically on the right side of the graph (green arrows). With respect to the statistics, the sample size does not permit an assumption of normality so we considered the statistical problem of separation of the projected samples using the nonparametric Mann–Whitney U-test. The obtained results are summarized in Table 2 (row A, bivariate analysis).
The second statistical test (the trivariate analysis) examined the three-dimensional data produced by differences in ‘recovery of scores’ (number of pellets retrieved, as illustrated in Fig. 2), ‘recovery of contact time’ (time to grasp first pellet, as illustrated in Fig. 4) and ‘lesion extent’, using a nonparametric multivariate rank test (Oja & Randles, 2004 ). This test includes all three parameters and can be considered an index of overall functional recovery. We assumed two independent random samples from bivariate distributions F(x-c1) and F(x-c2) located at centers c1 and c2, and tested the null hypothesis that there was no effect of treatment (i.e. c1 = c2 versus the alternative c1 is different from c2). Data were transformed to make the test affine-invariant, to ensure a consistent performance over all possible choices of coordinate system, and then projected onto a sphere where a rank test was performed. As the law for this test is still unknown, we used Monte-Carlo simulations to compute the P-value. The obtained results are summarized in Table 2 (row B, trivariate analysis). A complete description of these bivariate and trivariate statistical analyses, applicable also to other types of lesions and to other behavioral tests of manual dexterity in primates, will be reported elsewhere in a methodological report. The same two statistical analyses (bivariate and trivariate tests) were applied in a similar way as above for the estimated volume of the lesion (Table 2, rows C and D).
Full text: Click here
Publication 2009

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2012
Experimental procedures for tracer injections have been described previously52 (link). Briefly, double coinjections of anterograde and retrograde tracers were delivered to virtually all anatomically delineated regions of the cortex and into select regions of the amygdala and thalamus. Phaseolus vulgaris leucoagglutinin (PHAL; 2.5%; Vector Laboratories) and cholera toxin subunit b (AlexaFluor 647 conjugate, 0.25%; Invitrogen) were coinjected, while biotinylated dextran amine (BDA; FluoroRuby, 5%; Invitrogen) was injected in combination with Fluorogold (FG; 1%; Fluorochrome, LLC). Small localized injections (~200–500 μm) were confined within domains of cortical areas and produced consistent, specific, and highly topographic patterns across the rostral-caudal extent of the CP (Supplementary Fig. 1a). The labeling from PHAL injections was primarily used for automated quantification (see below). Multiple retrograde tracers were injected into different CP domains within a single animal to validate the anterograde tracing data (Supplementary Fig. 1b). Retrograde tracers included FG and CTb 647, 488, and 549 conjugates (0.25%; Invitrogen). Adeno-associated viruses encoding enhanced green fluorescent protein (AAV-GFP; AAV2/1.hSynapsin.EGFP.WPRE.bGH; Penn Vector Core) and tdTomato (AAV1.CAG.tdtomato.WPRE.SV40; Penn Vector Core) were used in cases in which multiple anterograde tracer injections were used to reveal direct spatial correlations of axonal terminals arising from different cortical areas (i.e., topography or interdigitation) (Supplementary Fig. 2a). Although the images in the paper are unique exemplars, the majority of injections were successfully repeated anywhere from 1–17 times (see Supplementary Table 1). For zQ175 and MAO A/B knockout mice, only PHAL tracer injections and labeling were used for quantification. Either one (PHAL) or three weeks (for AAV-GFP) was allowed for tracer transport after which animals were perfused and their brains were extracted.
Surgeries for tracer infusions were performed under isoflurane anesthesia (Hospira, Inc.). Mice were initially anesthetized in an induction chamber primed with isoflurane and were subsequently mounted to the stereotaxic apparatus where they were maintained under anesthetic state via a vaporizer (Datex-Ohmeda). The isoflurane was vaporized and mixed with oxygen (0.5 L/min) and nitrogen (1 L/min). The percent of isoflurane in the gas mixture was maintained between 2 and 2.5 throughout the surgery. Tracers were delivered iontophoretically using glass micropipettes whose outside tip diameters measured approximately 10–30 μm. A positive 5 μAmp, 7-second alternating injection current was delivered for 10 minutes (Stoelting Co.).
Publication 2016
Adeno-Associated Virus Alexafluor-647 Amygdaloid Body Anesthesia Anesthetics Animals biotinylated dextran amine Brain Choleragenoid Cloning Vectors Cortex, Cerebral enhanced green fluorescent protein Fluorescent Dyes Fluoro-Gold Isoflurane Kidney Cortex Mice, House Mice, Knockout Monoamine Oxidase B Nitrogen Operative Surgical Procedures Oxygen Phaseolus vulgaris leucoagglutinin Presynaptic Terminals Simian virus 40 tdTomato Thalamus Vaporizers
Procedures used to label three nerves with fluorescent tracers were similar to those described by May and Hill (2006) (link) and Mangold and Hill (2007) (link). Specifically, the CT, GSP, and IX nerves were labeled with anterograde tracers to determine the volume and spatial organization among the afferent nerve terminal fields in the rostral NTS during postnatal development. The density of the label was not quantified because of inaccuracies inherent in making and interpreting density measurements at the light microscopic level. Therefore, the terminal field volumes were calculated when any label, regardless of density, was present. This provides data on the topographical organization of the terminal fields but does not provide information concerning the absolute amount of afferent input into the NTS.
Rats were sedated with a 0.32 mg/kg injection of Domitor (medetomidine hydrochloride: Pfizer Animal Health, Exton, PA; I.M.) and anesthetized with 40 mg/kg Ketaset (ketamine hydrochloride: Fort Dodge Animal Health, Fort Dodge, IA; I.M.). A water-circulating heating pad was used to maintain body temperature. All rats except for those aged P15–P16 were positioned in a nontraumatic head holder. A ventral approach was taken in all rats to expose the CT and GSP nerves within the right tympanic bulla. The CT and GSP nerves were cut near the geniculate ganglion in the tympanic bulla and dimethyl sulfoxide (DMSO; Fisher Scientific Company, Fair Lawn, NJ) was briefly applied to the cut nerves. Crystals of 3-kD biotinylated dextran amine were then applied to the proximal cut end of the GSP and 3 kD Texas red dextran amine was applied to the proximal cut end of the CT (Fig. 1). A mixture of Vaseline and mineral oil was applied to prevent migration of dye. The IXth nerve was isolated just medial to the tympanic bulla and was cut and placed on a small piece of parafilm. Again, DMSO was applied briefly (~60 seconds) and crystals of 3-kD Cascade blue dextran amine were applied to the proximal cut end of the nerve (Fig. 1). All dextran amine conjugates were purchased from Invitrogen (Carlsbad, CA). The Vaseline and mineral oil mixture and a layer of parafilm were placed on top of the IXth nerve to keep the dye in place. Animals were then injected with 5 mg/kg Antisedan (atipamezole hydrochloride: Pfizer Animal Health; I.M.) to promote reversal of anesthesia. After an 18–24-hour survival, animals were deeply anesthetized with 4 mg/kg urethane (ethyl carbamate: Sigma-Aldrich Co., St. Louis, MO; I.P.) and transcardially perfused with Krebs-Henseleit buffer (pH 7.3), followed by 8% paraformaldehyde in PBS (pH 7.2).
We established previously (May and Hill, 2006 (link)) that 1) tracers placed on a nerve did not inadvertently label other nerves, 2) the full complement of fibers were labeled as revealed by examinations of the respective ganglia, and 3) the period of survival postsurgery was optimal for transport of each anterograde tracer. It should be noted that the mere presence of labeled terminal fields from GSP, CT, or IX axons does not necessarily mean that they convey taste information. For example, the three nerves also supply temperature and tactile information (Frank, 1968 ; Ogawa et al., 1968 (link); Smith et al., 1988 (link); Sollars and Hill, 1998 (link)). Thus, the NTS is a highly integrative center for multiple sensory inputs.
Publication 2008
Subjects were sedated with 1 mg/kg ketamine intramuscularly (i.m.), then anesthetized with 1.5–2.5% isofluorane. After mounting in a stereotaxic frame, a frontoparietal craniotomy was performed to expose both the right motor cortex. At each of 127 injection sites (59 locations, many at multiple depths; Fig. 1) in the right primary motor cortex, approximately 150 nanoliters of lysine-fixable biotinylated dextran amine (BDA; 10% in H20; 10,000 molecular weight; Molecular Probes, Eugene, OR) was injected with a pulled glass micropipette (outside diameter at tip ~40 μm) attached to a picospritzer (Parker Hannifin Corp., Fairfield, NJ). These sites included areas of motor cortex that innervate: 1) the hand and arm: 84 injections were made at 28 locations, 1.5 and 2.5 mm anterior to the central sulcus, spanning a territory from 13.3 to 24.5 mm lateral to the sagittal sinus and at depths in each site of 2.0, 3.5 and 5.5 mm (Fig. 1); 2) the trunk: 11 injections were made at 11 locations, 1.5 mm anterior to the central sulcus, spanning a territory from 3.9 to 12.5 mm lateral to the saggital sinus and at a depth of 2.2 mm (Fig. 1); 3) the foot and lower extremities: 32 injections were made at 20 locations, 2 and 3 mm lateral of the saggital sinus, spanning a territory from 1 to 11 mm anterior to the junction of the central sulcus and the saggital sinus and at depths ranging from 1.8 to 6.5 mm, (Fig. 1). After tracer injection, the craniotomy flap was replaced and the incision was closed.
Publication 2009
biotinylated dextran amine Cortex, Cerebral Craniotomy Foot Ketamine Lower Extremity Lysine Molecular Probes Motor Cortex Motor Cortex, Primary Reading Frames Sinuses, Nasal Surgical Flaps Transverse Sinuses Vascular Access Ports

Most recents protocols related to «Biotinylated dextran amine»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2024
Not available on PMC !
For axonal growth analysis, mice received an injection of 2 µL biotinylated dextran amine (BDA, 0.2 g/ml, Thermo Fisher Scientific, D1956, Waltham, MA) diluted in PBS at the cervical level two days prior to euthanasia. BDA was injected using a 1 mm sterile glass capillary needle attached to the micromanipulator arm mounted on a stereotactic frame (World Precision Instrument). Injections were made at a depth of 1 mm, 1.5 mm from the midline. The injection was carefully delivered within 1 minute. After injection, the muscles and skin were sutured.
Publication 2024

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2024
Adult mice were anesthetized with sodium pentobarbital and injected with 10% biotinylated dextran amine (BDA; MW10000, Invitrogen) into the right motor cortex. Six 0.2-μl aliquots were injected (0.1 μl/min) with a stereotaxic apparatus at the following coordinates: (i) A (anteriority) = 1, L (laterality) = 2, D (depth) = 1; (ii) A = 1, L = 1, D = 1; (iii) A = − 0.25, L = 2, D = 1; (iv) A = − 0.25, L = 1, D = 1; (v) A = − 1, L = 2, D = 1; and (vi) A= − 1, L = 1, D = 1. At each injection point, the needle was left in place for 5 min to minimize leakage.
Two weeks later, the mice were deeply anesthetized and perfused with 4% PFA. Brain slices were prepared as described above, incubated with streptavidin-Cy3 (1:1000; Jackson ImmunoResearch) and counterstained with Hoechst 33258 (1:2000; Sigma) to visualize BDA labeling.
Full text: Click here
Publication 2024
The materials and methods essentially followed those described previously (Liu et al., 2021 (link)) with minor modifications. Information about each monkey is summarized in Table 1. Four adult rhesus macaque monkeys (Macaca mulatta) were utilized in this study. Retrograde tracers, including cholera toxin subunit B conjugated with Alexa Fluor 488 (CTB-488; Thermo Fisher Scientific, MA), CTB conjugated with Alexa Fluor 555 (CTB-555; Thermo Fisher Scientific), CTB conjugated with Alexa Fluor 647 (CTB-647; Thermo Fisher Scientific), and biotinylated dextran amine 3,000 kDa (BDA; Thermo Fisher Scientific), were employed. Case 1 and Case 4 were previously subjected to separate electrophysiology studies in the motor cortex, and all four cases were involved in a distinct neuronal tracing study with CTBs and BDA injected into the prefrontal cortex of the other hemispheres. However, we consider that these treatments did not influence the results of the current study.
Full text: Click here
Publication 2024

Top products related to «Biotinylated dextran amine»

Sourced in United States
Biotinylated dextran amine (BDA) is a chemical compound used as a lab equipment product. It serves as a reagent for various biological applications.
Sourced in United States, United Kingdom
Alexa Fluor 488-conjugated streptavidin is a fluorescent labeling reagent used in various biological applications. Streptavidin is a tetrameric protein that binds strongly to the small molecule biotin. Alexa Fluor 488 is a fluorescent dye that is conjugated to the streptavidin, providing a fluorescent label that can be detected using appropriate instrumentation.
Sourced in France
The D-1956 is a laboratory instrument manufactured by Thermo Fisher Scientific. It is designed for general laboratory use and performs core functions related to sample analysis and preparation. The detailed specifications and intended applications of this product are not available in this response.
The BDA-3000 is a high-performance benchtop DNA analyzer designed for rapid and accurate genetic analysis. The instrument utilizes advanced fluorescence detection technology to perform DNA sequencing, fragment analysis, and sample identification. Key features include a compact design, user-friendly software interface, and reliable data processing capabilities.
Sourced in United States
Alexa Fluor 555-conjugated streptavidin is a fluorescent reagent that binds to biotin. It is used for detection and visualization in various research applications.
Sourced in United States
DAB staining is a laboratory technique used to detect the presence of specific proteins or other molecules within tissue samples. It involves the application of a chemical substrate that produces a brown stain when it interacts with the target analyte, allowing for visualization and identification of the desired target.
Sourced in United States, Germany
Fast Blue (FB) is a laboratory reagent used for staining and visualization purposes. It is a dye that can be used to detect the presence of specific biomolecules or cellular structures. The core function of Fast Blue is to provide a color contrast that allows for the identification and localization of target analytes in samples.
Sourced in United States, Germany, Italy
The Stereotaxic frame is a laboratory instrument used to immobilize and position the head of a subject, typically an animal, during surgical or experimental procedures. It provides a secure and reproducible method for aligning the subject's head in a three-dimensional coordinate system to enable precise targeting of specific brain regions.
Sourced in United States
The TSA Plus Biotin Kit is a laboratory equipment product from PerkinElmer. It is designed to amplify signal detection in various immunoassay techniques. The kit provides the necessary components to enhance the sensitivity of biotin-based detection systems.

More about "Biotinylated dextran amine"

Biotinylated dextran amine (BDA) is a versatile and powerful reagent used extensively in biomedical research.
It consists of a dextran backbone with biotin moieties attached, enabling the labeling and detection of target molecules.
This unique property makes BDA a valuable tool for tracking and visualizing cellular processes, protein interactions, and more.
BDA can be used in conjunction with various detection methods, such as Alexa Fluor 488-conjugated streptavidin or Alexa Fluor 555-conjugated streptavidin, to amplify the signal and enhance the visualization of labeled targets.
Additionally, techniques like DAB staining and Fast Blue (FB) can be employed to further enhance the detection capabilities of BDA.
Researchers leveraging the PubCompare.ai platform can easily identify the optimal protocols and products for their BDA-based studies, streamlining their workflow and achieving better results.
The AI-driven platform allows users to compare research protocols from literature, pre-prints, and patents, ensuring they have access to the most up-to-date and effective methodologies.
Whether you're working in cell biology, immunology, or molecular biology, BDA is a versatile reagent that can be a game-changer in your research.
By utilizing the power of PubCompare.ai's AI-driven platform, you can unlock the full potential of BDA and take your studies to new heights.
Expereince the convenience of a stereotaxic frame and the TSA Plus Biotin Kit to further enhance your BDA-based experiments.